What MicroPort (Shanghai) does

MicroPort (Shanghai) is a Chinese advanced medical device developer, manufacturer, and marketer founded in 1998 and listed on the Hong Kong Stock Exchange (00853.HK) since 2020. The company operates across 8-10 major business clusters spanning cardiovascular interventional devices (drug-eluting coronary stents Firehawk®, Firebird®, Firesorb®; TAVI systems VitaFlow®; drug-coated balloons), structural heart and cardiac rhythm management (pacemakers including world's smallest transvenous pacemaker, ICDs, left atrial appendage occluders), neurovascular devices (APOLLO® intracranial stents, Tubridge® flow diverters, NeuroHawk® thrombectomy stents, NUMEN® embolization coils), electrophysiology (Columbus® 3D mapping, IceMagic® cryoablation, PulseMagic® PFA catheters), aortic and peripheral vascular stent-grafts (Minos®, Castor®, Cratos®, Hector®, Talos®), surgical robotics (Toumai® laparoscopic robot with remote surgery capability, SkyWalker® orthopedic robot, R-one® vascular robot), orthopedic implants (Evolution® knee, hip systems, Cloudrider® shoulder), oncology (TACTIC® cryoablation), and digital health (Ticker™ Cockpit, remote ECG analysis, MicroGenius® autonomous surgery AI). The portfolio addresses approximately 200 diseases through 600+ medical solutions, supported by nearly 12,000 patent applications and 45+ NMPA Green Channel product designations.

The company generates revenue through direct B2B sales of high-end minimally invasive medical devices to hospitals and healthcare providers globally, supplemented by distributor networks across Asia Pacific, Europe, the Americas, Middle East, Africa, and Latin America. Major Chinese distribution operates through the Weilianweitong® agent network covering all provinces, while international markets are served via regional subsidiaries (North America HQ in Irvine, CA; manufacturing in Memphis, TN and Saluggia, Italy; offices in Tokyo, Amsterdam, Ratingen, Clamart). The company runs a sales-led go-to-market augmented by participation in major conferences (CMEF, CIT, TCT, PCR), eight international training centers, and the monthly MicroPort Biomedical Forum.

The MicroPort group has a multi-entity corporate structure with MicroPort Scientific Corporation (Cayman Islands) as the listed parent and four major independently-listed subsidiaries: Endovastec (688016.SH, 2019 IPO) for aortic and peripheral vascular, MicroPort MedBot (02252.HK, 2021) for surgical robotics, MicroPort NeuroScientific (02172.HK, 2021) for neurovascular, and MicroPort EP (688351.SH, 2022) for electrophysiology, plus MicroPort CardioFlow (02160.HK) for structural heart. The parent group retains controlling stakes while external investors hold minority positions in each listed subsidiary. Products reach 20,000+ hospitals across 100+ countries, with one MicroPort product used globally every 5 seconds on average.

Name

MicroPort (Shanghai)

Legal name

微创医疗科学有限公司

Website

https://microport.com.cn

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

MicroPort is a Chinese advanced medical device developer and manufacturer operating across cardiovascular, neurovascular, orthopedic, surgical robotics, electrophysiology, and oncology, serving 20,000+ hospitals in 100+ countries via direct sales and distribution networks.

Ownership category

akta.pro rank

Product category

Minimally Invasive Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

akta.pro secondary industries

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM)

Keywords

• Minimally invasive medical devices
• Interventional cardiology devices
• Neurovascular implants
• Surgical robotics systems
• Orthopedic implants

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices15 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical device product sales: Sale of high-end minimally invasive medical devices across multiple therapeutic areas including cardiovascular, neurovascular, orthopedic, surgical robotics, electrophysiology, and oncology. Products sold to hospitals and healthcare providers globally through direct sales and distributor networks.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

MicroPort Scientific Corporation develops, manufactures and globally markets high-end minimally invasive medical devices spanning drug-eluting coronary stents, transcatheter aortic valve systems, intracranial stents and flow diverters, cardiac rhythm management devices, multi-port and orthopedic surgical robots, electrophysiology mapping and ablation systems, orthopedic joint replacement implants, aortic stent-grafts, and tumor cryoablation systems. Products are sold to hospitals and healthcare providers in more than 100 countries and deployed in approximately 20,000 hospitals globally, supported by 8 international clinical training centers and a multi-subsidiary structure with regional R&D and manufacturing operations in China, the US, and Europe.

Product overview

MicroPort (Shanghai) is a comprehensive, global high-tech medical device group founded in 1998, listed on HKEX (00853.HK). The company operates across 10 major business segments covering cardiovascular, structural heart, neurovascular, electrophysiology, orthopedic, surgical robotics, urology/gynecology, tumor ablation, digital health, and rehabilitation. Its portfolio spans drug-eluting coronary stents (Firebird2®, Firehawk®, Firesorb®), transcatheter aortic valve systems (VitaFlow® series), cardiac rhythm management (pacemakers, ICDs), neurovascular devices (Tubridge®, APOLLO®, NeuroHawk®), surgical robots (Toumai® laparoscopy, SkyWalker® orthopedics, R-one® vascular), electrophysiology systems (Columbus®, IceMagic®, PulseMagic® PFA), aortic stent-grafts (Minos®, Castor®, Cratos®), orthopedic implants (Evolution® knee, hip systems), tumor cryoablation (TACTIC®), deep brain stimulation (Einstein®), tibial nerve stimulation (Streamliner™), and digital health AI platforms (Ticker™ Cockpit, remote ECG analysis, MicroGenius® autonomous surgery AI). The ecosystem includes ~600+ medical solutions serving 20,000+ hospitals globally.

Differentiator

Problem solved

Functional benefit

Brands

• 心脉医疗™: 胸主动脉及外周血管介入医疗器械业务板块
• 微创®心通
• 微创®机器人
• 微创脑科学™
• 微创®电生理
• 微创®骨科/MPO
• 微创神通
• 微创®优通
• 微创®视神
• 导向®医疗
• 火鹰®/Firehawk®
• Toumai®/图迈®
• 鸿鹄®/SkyWalker®
• 奇迹点®
• 悦肤达®/REVEDA®

Products and services

• Firebird2® Coronary Rapamycin Drug-Eluting Cobalt-Based Alloy Stent System Second-generation coronary rapamycin drug-eluting cobalt-based alloy stent system for treating coronary artery disease, sold to hospitals and interventional cardiologists.
• Firehawk® Coronary Rapamycin Targeted Drug-Eluting Stent System Targeted rapamycin drug-eluting coronary stent system with proprietary targeted drug delivery technology, for coronary artery disease treatment.
• FireCondor® Coronary Rapamycin Targeted Eluting Stent System Coronary rapamycin-targeted eluting stent system sold to interventional cardiology departments in hospitals across China and Europe.
• Firesorb® Bioresorbable Rapamycin-Eluting Coronary Stent System Bioresorbable rapamycin-eluting coronary scaffold with FUTURE-III 4-year clinical data showing lower late event rates than traditional metal stents, targeting interventional cardiology procedures.
• Firelimus® Coronary Rapamycin Drug-Coated Balloon (DCB) Coronary rapamycin drug-coated balloon catheter for 'intervention without implantation' treatment approach; approved in Hong Kong public healthcare system NPS.
• VitaFlow® Transcatheter Aortic Valve Implantation System Transcatheter aortic valve implantation system for treating aortic valve disease, with over 1,000 overseas commercial implants globally.
• VitaFlow Liberty® TAVI System with Retrievable Delivery Second-generation transcatheter aortic valve system with retrievable delivery catheter, covering nearly 40 countries globally.
• AnchorMan® Left Atrial Appendage Closure System Left atrial appendage closure device for stroke prevention in atrial fibrillation; approved in EU, Argentina, and Italy.
• Tubridge® Flow-Diverter Dense Mesh Stent Flow-diverter dense mesh stent for treating intracranial aneurysms, used by neurointerventional specialists.
• APOLLO™ Intracranial Artery Stent System Intracranial artery stent system including the APOLLO Dream® rapamycin-targeted eluting version; first NMPA-approved intracranial stent in China.
• Bridge® Vertebral Artery Rapamycin-Targeted Drug-Eluting Stent System Vertebral artery rapamycin-targeted eluting stent system with NMPA-approved 4.5mm and 5.0mm large diameter specifications.
• NeuroHawk® Intracranial Thrombectomy Stent Intracranial thrombectomy stent for acute ischemic stroke treatment, used by neurointerventional teams.
• HawkMaster™ Detachable Fibered Embolization Coil Detachable fibered embolization coil for peripheral vascular lesion embolization treatment, sold to interventional radiology departments.
• NUMEN® Detachable Embolization Coil Series Detachable embolization coil series (NUMEN FR, NUMEN Silk 3D electrolytic detachment coils, NUMEN Lighting electro-detachment coils) for aneurysm and vascular embolization.
• NuFairy® Bioresorbable Intracranial Coil Bioresorbable coil for intracranial aneurysm treatment.
• Toumai® Multi-Port Laparoscopic Surgical Robot System Multi-port laparoscopic surgical robot system with remote surgery capability, used by urology, general surgery, thoracic and gynecology departments in hospitals globally; first Chinese surgical robot to exceed 300 global commercial orders.
• Toumai® SP Single-Port Laparoscopic Surgical Robot System Single-port laparoscopic surgical robot system for minimally invasive procedures, expanding the Toumai robotic platform to natural-orifice and single-incision approaches.
• SkyWalker® Orthopedic Surgical Navigation and Positioning Robot Orthopedic surgical navigation and positioning robot for knee replacement, with NMPA, FDA and CE certifications; first Chinese orthopedic robot with international commercial deployment.
• R-one® Vascular Interventional Surgical Robot Vascular interventional surgical robot, first NMPA-approved and commercially deployed vascular intervention robot in China, also commercially deployed in Hong Kong.
• Mona Lisa Prostate Biopsy Localization Robot Prostate biopsy localization robot for precise robotic-assisted prostate biopsy procedures used in urology departments.
• Evolution® Total Knee Arthroplasty System Total knee arthroplasty system with 10-year NJR data showing revision rate of only 1.98%, paired with the NEXUS® femoral stem system for orthopedic surgery.
• Minos® Abdominal Aortic Stent-Graft System Abdominal aortic stent-graft system deployed in approximately 30 countries including the Netherlands with EU CE MDR certification.
• Castor® Branched Aortic Stent-Graft System Branched aortic stent-graft system for treating thoracoabdominal aortic aneurysms.
• Cratos® Branched Aortic Stent-Graft System Branched aortic stent-graft system deployed in Hungary, Germany, Italy, Spain, Switzerland, Netherlands, Denmark, and 10 European countries.
• Hector® Thoracoabdominal Multi-Branch Stent System Thoracoabdominal multi-branch stent system with FDA Breakthrough Device Designation, entered NMPA Green Channel, in pre-market clinical trials.
• Talos® Straight Thoracic Aortic Stent-Graft System Straight thoracic aortic stent-graft system for thoracic aortic aneurysm treatment.
• Fishhawk® Thrombectomy Device for DVT Thrombectomy device for percutaneous removal of acute iliac and femoral deep vein thrombosis (DVT).
• Reewarm® PTX Peripheral Drug-Coated Balloon Catheter Peripheral drug-coated balloon catheter, classified as a national innovative medical device product.
• SunFlow™ Drug-Eluting Peripheral Arterial Stent System Drug-eluting peripheral arterial stent system with dual-layer targeted sustained-release coating; the 10th HeartFlow product to enter NMPA Green Channel.
• Torqueflex™ Peripheral Micro-Catheter Peripheral micro-catheter for tumor embolization, combinable with PVA embolization microspheres for complete embolization treatment.
• Columbus® 3D Cardiac Electrophysiology Mapping System Three-dimensional cardiac electrophysiology mapping system for ablation procedure planning and guidance in electrophysiology labs.
• IceMagic® Cryoablation System (Cardiac EP) Cryoablation system for cardiac electrophysiology, the first Chinese cryoablation system to enter the European market (Germany clinical use).
• PulseMagic™ TrueForce® PFA Catheter (Pulsed Field Ablation) Pulsed field ablation catheter for atrial fibrillation, CE MDR certified via strategic partner Shangyang Medical and NMPA approved for cardiology use.
• EasyEcho™ Intracardiac Echocardiography (ICE) Catheter System Intracardiac echocardiography catheter with AI-powered real-time automated cardiac chamber reconstruction for electrophysiology procedures.
• ENO / Rega® / Trefle® / Orchidee® Series Implantable Cardiac Pacemakers Series of implantable cardiac pacemakers including the world's smallest transvenous pacemaker, with EU CE certification and LBBAP (left bundle branch area pacing) indication.
• Platinium™ Implantable Cardioverter-Defibrillator Implantable cardioverter-defibrillator for treating life-threatening arrhythmias.
• TACTIC® Cryoablation Tumor Treatment System Targeted cryoablation system using nitrogen-based Joule-Thomson effect for solid tumor treatment, available in single-channel, dual-channel, four-channel, and six-channel configurations; EU CE MDR certified.
• TomaHawk® Coronary Intravascular Lithotripsy (IVL) Catheter System Intravascular lithotripsy catheter system for treating high-resistance calcified coronary lesions; received Shanghai Design 100+ award.
• FireFalcon® Coronary Scoring Balloon Dilation Catheter Coronary scoring balloon dilation catheter used in interventional cardiology to prepare lesions for stent deployment.
• Einstein® Deep Brain Stimulation System (DBS) Targeted deep brain stimulation (brain pacemaker) system for treating Parkinson's disease and other neurological disorders.
• Streamliner™ Implantable Tibial Nerve Stimulator Implantable tibial nerve stimulator for overactive bladder treatment.
• DFVision® 3D Electronic Laparoscope System 3D electronic chest-abdominal endoscope system for laparoscopic visualization in operating rooms.
• YINI® Cataract Phacoemulsification System Cataract phacoemulsification system for ophthalmic surgery to treat cataracts.
• YairDent® Dental Implant System Dental implant system with UltraSLA surface treatment technology for enhanced osseointegration in dental restoration.
• Cloudrider™ Shoulder Joint Replacement System Shoulder joint replacement system for orthopedic shoulder arthroplasty procedures.
• MicroPort YouTong® 8 Urology Products (EU CE MDR) Line of urology products from MicroPort YouTong sold to urology departments in European hospitals with CE MDR certification.
• MicroGenius® Multimodal Autonomous Surgery AI Model Multimodal autonomous surgery AI model enabling soft tissue robotic surgery to be performed autonomously by a central AI for surgical robotics applications.
• Ticker™ Cockpit Cardiovascular Digital Cloud Platform Cardiovascular digital cloud platform for integrated monitoring and analysis of patient physiological data, sold to hospitals and care teams managing chronic cardiovascular disease.
• Remote ECG Analysis Software Remote ECG analysis software enabling AI-powered ECG waveform analysis and diagnostic reporting for cardiology departments.

Quantifiable outcome

• One MicroPort product used globally every 5 seconds on average
• +4 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core.

• Fudan University Affiliated Zhongshan HospitalcoreStrategic or Co-development Partner · 25 June 2026Multi-modal AI intelligent diagnosis and treatment system research project for vascular endovascular intervention. The collaboration aims to advance AI-enabled vascular surgery technology and clinical translation.
• Shanghai Weiyidian Digital Technology Co., Ltd. (微分易数)coreStrategic or Co-development PartnerAI-enabled vascular surgery research and development partnership, part of MicroPort's digital transformation strategy.
• Shandong Provincial People's HospitalcoreStrategic or Co-development PartnerRemote surgery collaboration and training partner for Toumai surgical robot.
• Gansu Provincial People's HospitalcoreStrategic or Co-development PartnerRemote surgery collaboration partner for Toumai surgical robot in Western China.
• Shanghai University of Science and Technology (Shanghai Lixin)coreStrategic or Co-development PartnerJoint establishment of Modern Minimally Invasive Medical Devices and Technology Engineering Research Center, approved by Ministry of Education. Joint investment in joint-stock system engineering center.
• Shanghai Shangyang Medical Technology Co., Ltd. (商阳医疗)coreStrategic or Co-development PartnerStrategic partner for PFA (pulse field ablation) systems. PulseMagic PFA system received CE MDR certification through this partnership.
• 8 International Training CenterscoreStrategic or Co-development PartnerEstablished 8 international training centers in Shanghai, Orlando, Strasbourg, Belgium, Istanbul, Sao Paulo, Bangkok, and Luanda for surgical robot training and clinical education.
• Turkey Kosuyolu Hospital and Korea Ewha Womans University HospitalcoreStrategic or Co-development PartnerRegional training centers for EndOvastec in Eurasia and Asia-Pacific regions for aortic and peripheral vascular intervention training.

Scale indicators15 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Stryker: Major medical device company with Mako surgical robotics system for orthopedics and broad orthopedic implants portfolio. Direct competitor with MicroPort's SkyWalker orthopedic surgical robot and Evolution/Profemur joint replacement systems.
• Medtronic: Global medical device leader with overlapping cardiovascular (stents, TAVI, CRM), neurovascular, surgical (Hugo robot), and diabetes franchises. Largest incumbent competing against MicroPort across nearly every therapeutic area.
• Boston Scientific: Major cardiovascular and interventional medical device company with strong peripheral vascular, structural heart, EP, and neuromodulation businesses—direct competitors in coronary stents, TAVI, EP ablation, and DBS.
• Abbott: Global healthcare company with significant cardiovascular (XIENCE coronary stents, MitraClip), CRM, diabetes, and diagnostics businesses. Direct competitor in coronary stents, structural heart, and cardiac rhythm management.

Direct peers

• Penumbra: US neurovascular company specializing in stroke treatment (thrombectomy, aspiration) and embolization devices. Direct competitor with MicroPort's NeuroHawk thrombectomy stent and NUMEN/HawkMaster embolization coil portfolio.
• Edwards Lifesciences: Global leader in transcatheter heart valves (SAPIEN TAVI platform) and structural heart. MicroPort's VitaFlow TAVI directly competes in the same transcatheter aortic valve replacement market with the same clinical applications.
• Venus MedTech: China-based structural heart company focused on transcatheter heart valves. Direct competitor in the Chinese TAVI market against MicroPort's VitaFlow system, both targeting aortic and mitral valve replacement opportunities.
• Peijia Medical: China-based interventional medical device company with TAVI and structural heart products. Direct competitor in Chinese structural heart market and overlapping neurovascular device offerings.
• Intuitive Surgical: Dominant surgical robotics incumbent (da Vinci system) with multi-port laparoscopic platform. MicroPort's Toumai multi-port robot is positioned as a competing surgical robotics platform targeting urology, general surgery, thoracic, and gynecology applications.
• Shockwave Medical (Johnson & Johnson MedTech): Intravascular lithotripsy (IVL) pioneer now part of J&J MedTech. Direct competitor with MicroPort's TomaHawk intravascular lithotripsy catheter system for treating calcified coronary lesions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/microport-lifescience-co--ltd

Compliance30 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries22 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MicroPort (Shanghai)